What happened, in summary

Rosemary Conway was 60 when she was diagnosed with lung cancer in August 2017 after developing a raspy voice and coughing up a small amount of blood. She had never smoked and was an active runner. In September, surgeons removed the lower lobe of her left lung and a plum-sized mass. The following month, she had the upper right lobe removed with an apple-sized mass. Rosemary then received chemotherapy, but the cancer returned about 7 months later. Testing identified a KRAS G12D mutation. Over the following years, she participated in 3 clinical trials. Two did not control the cancer, and she later underwent several courses of radiation and proton therapy. In December 2023, at age 68, Rosemary entered a trial of daraxonracib, a targeted drug designed to block RAS-driven cancer. She took the treatment as a nightly pill. After 14 months, her cancer had stopped growing. She was back in the gym, walking and lifting weights, while also advocating for other people with lung cancer.